LARIO THERAPEUTICS

FIGHTING
NEUROLOGICAL
DISORDERS WITH
PRECISION
MEDICINE

Precision Neuroscience
Today

Lario Therapeutics are developing first-in-class precision medicines as disease modifying treatments for severe neurological disorders including epileptic conditions and Parkinson’s disease. Our rapidly advancing pipeline begins with genetically validated targets and promises broad therapeutic potential, with a chance to slow the progression of these devastating early childhood syndromes and adult neurological disorders.

OUR SCIENCE

LATEST NEWS

Jul 22

Lario Therapeutics awarded $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research

Award supports preclinical research of Lario’s CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of...

May 31

Lario Therapeutics invited to present at the CACNA1E International Family Conference

Munich, Germany, 21 May 2024: Lario Therapeutics CEO Henning Steinhagen and CSO Tom Otis were invited to the inaugural CACNA1E Family...

Nov 7, 2023

Lario Therapeutics receives “Company Making a Difference Award” from CDLK5 Forum, recognising its unique approach to precision medicine for genetic epilepsies

“CDLK5 Forum Award for Excellence - Company Making a Difference 2023 Pre-clinical” presented by the Loulou Foundation at the CDKL5 Forum,...

Breakthrough personalized medicine approaches for neurological disorders

OUR COMPANY

Lario Therapeutics was founded in 2021 as a spin-out from Epidarex Exeed, the therapeutic discovery engine of Epidarex Capital, with seed investment from Epidarex Capital and Axxam (which transferred to Golgi Neurosciences)

Targeting severe developmental & epileptic encephalopathies and neurodegenerative disorders

OUR PIPELINE

First-in-class precision medicines for disease modifying treatments in severe neurological disorders including epileptic conditions and Parkinson’s disease. Rapidly advancing a pipeline of genetically validated programs towards the clinic.